NCT03532425View on ClinicalTrials.gov

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

PHASE4TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

August 3, 2020

Study Completion Date

September 3, 2020

Conditions
HIV-1-infection
Interventions
DRUG

B/F/TAF

B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily

DRUG

Atripla

Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily

DRUG

B/F/TAF Placebo

Tablet taken orally once daily

DRUG

Atripla Placebo

Tablet taken orally once daily

Trial Locations (1)

T6G 2B7

University of Alberta, Edmonton

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

University of British Columbia

OTHER

lead

University of Alberta

OTHER